Table 4.
Parameters | Univariate analysis |
Multivariate analysis |
||||
---|---|---|---|---|---|---|
†OR (95% CI) | p-value | Model 1 |
Model 2 |
|||
OR (95% CI) | p-value | OR (95% CI) | p-value | |||
Body surface area | ||||||
<1.5 | 1 | |||||
1.5–1.75 | 0.68 (0.45–1.04) | 0.07 | ||||
>1.75 | 1.03 (0.62–1.72) | 0.91 | ||||
Cardiovascular co-morbidity | ||||||
No | 1 | |||||
Yes | 0.56 (0.27–1.14) | 0.11 | ||||
HIV/AIDS | ||||||
No | 1 | |||||
Yes | 0.62 (0.30–1.26) | 0.19 | ||||
Baseline leukocyte toxicity grade | ||||||
Normal‡ | 1 | 1 | ||||
Grade 1£ | 3.20 (2.02–5.08) | < 0.001 | 2.75 (1.47–5.15) | < 0.001 | ||
Baseline neutrophil toxicity grade | ||||||
Normal‡ | 1 | 1 | ||||
Grade 1§ or Grade 2¥ | 2.32 (1.58–3.41) | < 0.001 | 2.75 (1.73–4.35) | < 0.001 | ||
CYP3A5 | ||||||
∗1/∗1 | 1 | 1 | 1 | |||
∗3 carriers | 2.34 (1.03–5.32) | 0.042 | 2.04 (0.87–4.79) | 0.05 | 2.12 (0.90–4.96) | 0.08 |
CYP2C9 | ||||||
∗1/∗1 | 1 | 1 | 1 | |||
∗2 or ∗3 carriers | 0.35 (0.14–0.88) | 0.024 | 0.40 (0.13–1.18) | 0.10 | 0.49 (0.19–1.22) | 0.12 |
CYP2C19 | ||||||
∗1/∗1 | 1 | |||||
∗2 or ∗3 carriers | 1.08 (0.76–1.54) | 0.66 | ||||
CYP2J2 | ||||||
∗1/∗1 | 1 | 1 | 1 | |||
∗7 carriers | 1.66 (1.05–2.64) | 0.032 | 1.82 (1.14–2.9) | 0.012 | 1.74 (1.09–2.78) | 0.021 |
POR | ||||||
∗1/∗1 | 1 | |||||
∗28 carriers | 0.95 (0.58–1.56) | 0.83 | ||||
ABCB1 rs 3842 A>G | ||||||
AA | 1 | |||||
G carriers | 0.75 (0.35–1.62) | 0.46 |
†Odds ratio; ‡4,500–10,000/m3; £3,000–4,500/mm3; d'2,500–7,500/m3; §1,500–2,500/m3; ¥1,000–1,500/m3.